In the age of novel therapies, what defines high-risk multiple myeloma?

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 8, Issue SUPPL. 1, 2010, Pages

  Badros, Ashraf ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

Allogeneic stem cell transplantation; Bortezomib; Chromosomal abnormalities; Lenalidomide; Risk stratification; Thalidomide

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN HEAVY CHAIN; LENALIDOMIDE; MELPHALAN; PLACEBO; PREDNISONE; THALIDOMIDE;

ADD ON THERAPY; ANEUPLOIDY; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CHROMOSOME 13; CHROMOSOME 14; CHROMOSOME 17P; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; CONFERENCE PAPER; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE LOCATION; GENETIC ANALYSIS; GENETIC VARIABILITY; HEALTH CARE ORGANIZATION; HIGH RISK POPULATION; HUMAN; KARYOTYPING; MICROARRAY ANALYSIS; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OVERALL SURVIVAL; PRACTICE GUIDELINE; PROGNOSIS; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77649151227     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2010.0114     Document Type: Conference Paper

References (39)

1. Rajkumar SV, Buadi F. Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation. Best Pract Res Clin Haematol 2007;20:665-680.
2. Horner MJ, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2006. Available at: http://seer.cancer.gov/csr/1975-2006. Accessed May 8, 2009.
3. Stewart AK, Fonseca R. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol 2005;23:6339-6344.
4. Stewart AK, Bergsagel PL, Greipp PR, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007;21:529-534.
5. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004;64:1546-1558.
6. Dewald, GW, Therneau T, Larson D, et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood 2005;106:3553-3558.
7. Chang, H, Qi XY, Samiee S, et al. Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation. Bone Marrow Transplant 2005;36:793-796.
8. Gertz MA, Lacy MQ, Dispenzieri A, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005;106:2837-2840.
9. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 2007;109:3489-3495.
10. Chang, H, Sloan S, Li D, et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004;125:64-68.
11. Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007;109:2276-2284.
12. Zhan F, Barlogie B, Mulligan G, et al. High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. Blood 2008;111:968-969.
13. Decaux, O, Lode L, Magrangeas F, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. J Clin Oncol 2008;26:4798-4805.
14. International Myeloma Workshop. Guidelines for risk stratification in multiple myeloma. Report of the 2008 International Myeloma Workshop Consensus Panel 2. Available at http://www.mwdelhi09.com/spargoDocs/Consensuspaneltwo.pdf. Accessed June 10, 2009.
15. Dispenzieri, A, Rajkumar SV, Gertz MA, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007;82:323-341.
16. Rajkumar SV, Kyle RA. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 2005;80:1371-1382.
17. Anderson KC, Alsina M, Bensinger W, et al. NCCN clinical practice guidelines in oncology: multiple myeloma, v2.2010. Available at www.nccn.org. Accessed July 31, 2009.
18. Fonseca R. Strategies for risk-adapted therapy in myeloma. Hematology Am Soc Hematol Educ Program 2007;304-310.
19. Dispenzieri, A, Jacobus S, Vesole DH, et al. Primary therapy with bortezomib - the role of induction, maintenance, and re-induction in patients with high risk myeloma: update of results from E2A02 [abstract]. Presented at the 2008 American Society of Hematology Annual Meeting; December 6-9, 2008; San Francisco, California. Abstract 1738.
20. Knop S, Liebisch P, Wandt H, et al. Bortezomib, IV cyclophosphamide, and dexamethasone (VelCD) as induction therapy in newly diagnosed multiple myeloma: results of an interim analysis of the German DSMM Xia trial [abstract]. Presented at the 2009 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2009; Orlando, Florida. Abstract 8516.
21. Kapoor P, Kumar S, Fonseca R, et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2009;114:518-521.
22. Zonder J, Crowley J, Bolejack V, et al. A randomized Southwest Oncology Group study comparing dexamethasone to lenalidomide + dexamethasone (LD) as treatment of newly diagnosed multiple myeloma: impact of cytogenetic abnormalities on efficacy of LD, and updated overall study results [abstract]. Presented at the 2008 American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2008; Chicago, Illinois. Abstract 8521.
23. Kapoor P, Kumar S, Greipp PR, et al. Prognostic impact of the plasma cell labeling index (LI) in newly diagnosed myeloma patients treated with thalidomide-dexamethasone (thal/dex) or lenalidomide-dexamethasone (len/dex) [abstract]. Presented at the 2008 American Society of Hematology Annual Meeting; December 6-9, 2008; San Francisco, California. Abstract 1729.
24. Zangari M, van Rhee F, Anaissie E, et al. Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1. Br J Haematol 2008;141:433-444.
25. Waheed S, Shaughnessy J, Szymonifka, J, et al. Benefit of thalidomide in Total Therapy 2 (TT2) of multiple myeloma exhibiting both cytogenetic abnormalities and low risk by gene expression profiling [abstract]. Presented at the 2009 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2009; Orlando, Florida. Abstract 8590.
26. Cavo, M, Testoni N, Terragna C, et al. Superior rate of complete response with up-front Velcade-thalidomide-dexamethasone versus thalidomide- dexamethasone in newly diagnosed multiple myeloma is not affected by adverse prognostic factors, including high-risk cytogenetic abnormalities [abstract]. Presented at the 2008 American Society of Hematology Annual Meeting; December 6-9, 2008; San Francisco, California. Abstract 1662.
27. Pineda-Roman M, Zangari M, Haessler J, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol 2008;140:625-634.
28. Richardson P, Lonial S, Jakubowiak A, et al. Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phase I/II study [abstract]. Presented at the 2008 American Society of Hematology Annual Meeting; December 6-9, 2008; San Francisco, California. Abstract 92.
29. Landau H, Hassoun H, Cohen A, et al. Sequential administration of bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone results in rapid control of untreated high-risk multiple myeloma and improves depth of response [abstract]. Presented at the 2008 American Society of Hematology Annual Meeting; December 6-9, 2008; San Francisco, California. Abstract 3712.
30. Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006;108:2165-2172.
31. Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica 2008;93:560-565.
32. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N EnglJ Med 2008;359:906-917.
33. Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA - Italian Multiple Myeloma Network. J Clin Oncol 2007;25:4459-4465.
34. Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001;97:2574-2579.
35. Badros A, Barlogie B, Siegel, et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002;20:1295-1303.
36. Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (1FM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006;107:3474-3480.
37. Moreau P, Hullin C, Garban F, et al. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood 2006;107:397-403.
38. Rotta M, Storer BE, Sahebi F, et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood 2009;113:3383-3391.
39. Schilling G, Hansen T, Shimoni A. et al. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2008:22:1250-1255.